Differentiated thyroid carcinoma (DTC) is currently one of the most rapidly increasing tumours. And it is predicted to continue to rise over the next 10 years (1). Surgery to remove the entire thyroid gland remains the gold standard treatment for low-risk DTC with (tumour size between 1cm to 4cm). The extent of thyroid resection for low-risk disease however is controversial. Until recently, the standard of care has been a 'one size fits all' approach of total-thyroidectomy (TT) for \>1cm DTC. This treatment has afforded excellent overall survival rate (98-99% at 10-year) and a low recurrence rate (2-8% at 7-year) (2). However, based on recent studies, national guidelines (American Thyroid Association 2015 and British Thyroid Association 2014) now propose hemithyroidectomy (HT) as potentially adequate treatment in low-risk DTC (3,4). This is because TT does not appear to offer an overall survival advantage over HT, and subject patients to life-long hormone replacement therapy and perhaps an increased risk of postoperative complications. However, the recent change in guidance is only based on retrospective and observational single-centre studies which are subject to various types of bias (5). A clear "surgical equipoise" therefor exists for managing low-risk thyroid cancer patients. When faced with this equipoise, where clinicians are not sure and data are still equivocal, it is even more difficult for patients to understand the issues and make a treatment choice that is best for their individual needs and priorities. Due to the excellent prognosis, there is an ever-increasing pool of cancer-survivors in whom long-term quality-of-life (QoL) is more important than cure rates. Many thyroid cancer patients have severe anxiety and long-term problems resulting in low QoL. Unfortunately, a recent National Patient Survey showed that existing clinical equipoise (and resulting practice variation) has resulted in high levels of confusion, dissatisfaction, and anxiety in patients with regards to treatment decision (6). Enabling better patient decision-making to choose the best treatment choice should lead to an improved patient experience, higher satisfaction, better QoL and reduced health burden on the NHS (7).

Patient concerns inventory (PCI) is a condition-specific prompt list which allows patient to formulate an individualised record of their concerns, needs and priorities that can be used as a structure to help guide out-patient consultations (8). Patients identify, in advance of consultations, salient issues from a specifically designed questionnaire prompt list (PCI). This allows clinicians to focus dialogue quickly on patients' main concerns and to address issues that patients might be otherwise have been reluctant to discuss. The original PCI was developed by Professor Simon Rogers, consultant oral and maxillofacial surgeon of Aintree University Hospital, Liverpool, in 2009 to provide a patient focused approach to managing head and neck cancer (8). Since then, PCIs have also been successfully developed in other disciplines such as breast cancer (9), burns (10), rheumatology (11), stroke care and diabetes.

Recently we have developed a thyroid-specific patient concerns inventory (PCI-TC) \[see Appendix for Thyroid Concerns Inventory\] from literature review on the unmet needs of thyroid cancer patients followed by two phases and six rounds of modified Delphi process within a thyroid cancer multi-disciplinary team (MDT). We hope the use of PCI-TC at diagnosis will help tease out patient's top concerns and expectations regarding their treatment and care going forward, thus enhancing shared decision making (SDM), so that they are better informed and have confidence in their treatment preferences/choices within the current equipoise.